Tag
This nationwide Finnish cohort study reveals that gout increases ischemic stroke risk in atrial fibrillation patients, with urate-lowering therapy linked to reduced stroke incidence, underscoring gout’s potential role in stroke risk s
Achieving serum urate targets <6 mg/dL (or <5 mg/dL) through Treat-to-Target (T2T) protocols significantly reduces major adverse cardiovascular events in gout patients, particularly those at high baseline risk.
The 5-year NOR-Gout study demonstrates that sustained low serum urate via treat-to-target therapy leads to dissolution of crystal deposits, reduced flares, and increased remission rates, highlighting the clinical value of long-term urate co
Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to hig
Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12
